Rotenone as a Mitochondrial Dysfunction Inducer: Insights into Metabolic Regulation and Disease Modeling

Introduction

Understanding mitochondrial dysfunction has become central to unraveling the complex pathophysiology underlying neurodegenerative diseases, metabolic syndromes, and cellular aging. Among chemical probes, Rotenone (CAS 83-79-4) stands out as a canonical mitochondrial Complex I inhibitor, selectively disrupting the electron transport chain (ETC) and thereby serving as a robust tool for interrogating mitochondrial biology. While previous reports have emphasized Rotenone’s role in simulating Parkinsonian pathology and mitochondrial impairment, recent advances in mitochondrial proteostasis, such as the regulation of a-ketoglutarate dehydrogenase (OGDH) by the DNAJC co-chaperone TCAIM, have highlighted new dimensions in the study of mitochondrial metabolism and its intersection with cellular signaling (Wang et al., Molecular Cell, 2025).

Rotenone: Mechanism of Action as a Mitochondrial Complex I Inhibitor

Rotenone’s primary mode of action is the inhibition of mitochondrial Complex I (NADH:ubiquinone oxidoreductase), a critical entry point for electrons into the ETC. By binding to Complex I, Rotenone impedes electron transfer from NADH to ubiquinone, resulting in a collapse of the mitochondrial proton gradient and impairment of ATP synthesis. This disruption triggers excessive formation of reactive oxygen species (ROS), leading to oxidative damage and activation of stress-responsive signaling pathways. With an IC₅₀ of 1.7–2.2 μM, Rotenone’s potency enables precise titration of mitochondrial dysfunction in vitro and in vivo. The compound’s solubility profile—insoluble in water and ethanol but highly soluble in DMSO (≥77.6 mg/mL)—makes it suitable for diverse experimental protocols, provided stock solutions are freshly prepared and stored below -20°C to preserve activity.

Applications in Cellular Models: Apoptosis and Autophagy Pathways

Rotenone’s capacity to induce mitochondrial dysfunction has made it indispensable for investigating apoptosis, autophagy, and related signaling pathways. Notably, in differentiated SH-SY5Y neuroblastoma cells, Rotenone functions as a robust apoptosis inducer, promoting cytochrome c release, caspase-3 activation, and subsequent cell death. At submicromolar concentrations (e.g., 50 nM), Rotenone produces a biphasic survival curve over extended periods, mirroring the progressive nature of neuronal degeneration. Furthermore, Rotenone’s effects on mitochondrial dynamics—such as reduced mitochondrial movement—offer mechanistic insights into the interplay between mitochondrial integrity and neuronal viability.

Rotenone is also frequently employed in autophagy pathway research and caspase activation assays. The compound’s ability to elevate intracellular ROS serves as a trigger for autophagic flux and modulates MAP kinase signaling, including the p38 MAPK and JNK pathways. These features make Rotenone a versatile agent for dissecting the crosstalk between oxidative stress, apoptosis, and cellular repair mechanisms.

Animal Models: Parkinson’s Disease and Neurodegenerative Research

In vivo, Rotenone’s selective neurotoxicity has been exploited to generate animal models of Parkinson’s disease and related disorders. Intranasal or systemic administration of Rotenone recapitulates hallmark features of Parkinsonian pathology, including dopaminergic neurite degeneration in the substantia nigra and olfactory dysfunction. This relevance to neurodegenerative disease research extends Rotenone’s utility beyond cellular models, enabling the exploration of disease mechanisms, therapeutic targets, and neuroprotective interventions under physiologically relevant conditions.

ROS-mediated cell death induced by Rotenone in neuronal circuits provides a robust platform for studying the progressive loss of neuronal populations. These models are instrumental in evaluating novel neuroprotective agents and unraveling the molecular underpinnings of synaptic dysfunction, mitochondrial biogenesis, and protein aggregation.

Interfacing Rotenone-Induced Dysfunction with Mitochondrial Proteostasis: Lessons from TCAIM and OGDH Regulation

While Rotenone’s role as a mitochondrial Complex I inhibitor is well established, recent discoveries regarding mitochondrial proteostasis add new layers to our understanding of metabolic regulation. The study by Wang et al. (Molecular Cell, 2025) identifies TCAIM, a DNAJC-type co-chaperone, as a pivotal regulator of OGDH protein levels. TCAIM mediates the selective reduction of OGDH via interaction with HSPA9 and LONP1, leading to decreased OGDH complex activity and altered mitochondrial metabolism. This post-translational control of a rate-limiting TCA cycle enzyme demonstrates that mitochondrial metabolic output is not solely dictated by substrate availability or redox state, but also by dynamic protein quality control mechanisms.

Integrating Rotenone-induced mitochondrial dysfunction with the regulation of OGDH by TCAIM provides a unique experimental framework. Whereas Rotenone acutely impairs electron transport and ATP production, TCAIM-mediated OGDH downregulation chronically modulates metabolic flux through the TCA cycle. Together, these approaches enable researchers to dissect the temporal and mechanistic interplay between ETC inhibition, TCA cycle activity, and downstream cellular responses.

Experimental Considerations for Using Rotenone in Advanced Mitochondrial Research

Leveraging the full potential of Rotenone in research requires a nuanced understanding of its pharmacodynamics, solubility, and storage requirements. For precise caspase activation assays and autophagy pathway research, Rotenone should be dissolved in DMSO at concentrations ≥77.6 mg/mL, with aliquots stored at -20°C to prevent degradation. Given its insolubility in water and ethanol, care must be taken to avoid precipitation in aqueous media. The timing and concentration of Rotenone exposure are critical, as prolonged treatment at sublethal doses can produce biphasic survival curves and reveal adaptive or compensatory pathways in cell populations.

In animal studies, delivery routes (e.g., intranasal versus systemic) and dosing regimens should be tailored to recapitulate specific aspects of neurodegeneration or mitochondrial impairment. For example, intranasal Rotenone administration has been shown to selectively target dopaminergic neurons and impair olfactory function, offering a model for early-stage Parkinson’s disease.

New Perspectives: Rotenone and the Integration of Mitochondrial Signaling Pathways

Recent interest in the intersection of mitochondrial dysfunction, proteostasis, and cellular signaling highlights the need for integrated experimental strategies. Rotenone-induced ROS not only damages macromolecules but also serves as a signaling intermediate, activating kinases such as p38 MAPK and JNK. These stress-responsive pathways converge on transcriptional regulators and apoptosis machinery, linking mitochondrial distress to nuclear gene expression and cell fate decisions.

By combining Rotenone-induced ETC inhibition with genetic or pharmacological manipulation of mitochondrial chaperones and proteases (such as TCAIM, HSPA9, and LONP1), researchers can interrogate how mitochondrial protein quality control intersects with bioenergetics and cell death pathways. Such combinatorial approaches are poised to yield new insights into the progression of neurodegenerative diseases, the adaptation of cancer cells to metabolic stress, and the development of targeted therapeutics.

Conclusion

Rotenone remains a cornerstone in mitochondrial research, enabling precise modulation of Complex I activity, ROS generation, and downstream cell signaling. Its integration with emerging discoveries in mitochondrial proteostasis—such as the regulation of OGDH by TCAIM—offers expanded opportunities for dissecting metabolic pathways, apoptosis, and disease mechanisms. As the field advances, strategic use of Rotenone alongside genetic and proteomic tools will be essential for elucidating the multifaceted roles of mitochondria in health and disease.

While prior articles such as "Rotenone: A Mitochondrial Complex I Inhibitor for Neurodegenerative Disease Modeling" have focused on neurodegenerative models and canonical apoptosis pathways, this article extends the discussion by explicitly integrating recent findings on mitochondrial proteostasis and the regulation of metabolic enzymes like OGDH by TCAIM. This broader perspective provides researchers with a conceptual framework to explore Rotenone’s utility not only as a mitochondrial dysfunction inducer, but also as a tool for probing the dynamic interplay between bioenergetics, proteostasis, and cell signaling in complex disease contexts.